The CEO and two other executives at Hyloris Pharmaceuticals are leaving their posts as part of company-wide changes, as the company continues to wrestle with new developments linked to how it accounted for its in-licensing transactions with the Dutch business QliniQ.
Originally announced in January 2023, Belgian value added medicines specialist Hyloris stated that it had acquired global rights to the...




